Investors
Opyl is headquartered in Melbourne, Australia and listed on the Australian Stock Exchange (ASX:OPL)
ASX Announcements
Opyl delivers world-first in mapping and linking global clinical trial outcome data
downloadOpyl receives $570K R&D tax refund
downloadClarification to ASX announcement of 28 September 2022
downloadOpin forms strategic partnership and new services for better clinical trial outcomes and scale
downloadOpyl Full Year FY22 Results Announcement
downloadOpyl partners with leading patient advocate groups
downloadQuarterly Reports
Opyl Appendix 4C – Quarter (Q1) ending 30 September 2022
downloadOpyl Appendix 4C – Quarter (Q4) ending 30 June 2022
downloadOpyl Appendix 4C – Quarter (Q3) ending 31 March 2022
downloadOpyl Appendix 4D – Half-year ending 31 December 2021
downloadOpyl Appendix 4C – Quarter (Q2) ending 31 December 2021
downloadOpyl Appendix 4C – Quarter (Q1) ending 30 September 2021
downloadCorporate Governance
Opyl – Corporate Governance Statement 2022
downloadOpyl – Constitution 2022
downloadOpyl – Audit and Risk Committee Charter 2020
downloadOpyl – Board Charter 2020
downloadOpyl – Code of Conduct 2020
downloadOpyl – Diversity Policy 2020
downloadOpyl – Remuneration and Nomination Committee Charter 2020
downloadOpyl – Trading Policy 2020
downloadOpyl – Whistleblower 2020
downloadOpyl – Disclosure and Communication Policy 2020
downloadOpyl – Appendix 4G
downloadBoard and Management Team
Mark Ziirsen
Chairman
Michelle Gallaher
Chief Executive Officer
Damon Rasheed
Executive Director
Dr Julian Chick
Non Executive Director
Dr Megan Robertson
Non Executive Director
David Iilja
Company Secretary